Thermo Fisher Scientific announces the availability of its Copeptin assay in Europe

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the availability in Europe of its new Copeptin assay, which helps medical personnel quickly and accurately diagnose acute myocardial infarction (AMI), commonly known as a heart attack. Copeptin, developed by recently acquired B.R.A.H.M.S. AG, is a patented biomarker for AMI and is detectible using a simple blood test that, in combination with a Troponin biomarker test, permits doctors to rule out or confirm the onset of a heart attack within minutes. Currently, physicians rely on an electrocardiogram in combination with Troponin which, in most patients with chest pain, cannot indicate AMI until at least 4 hours after the onset of symptoms and requires additional testing after 6 to 9 hours.

“We acquired B.R.A.H.M.S. to strengthen our specialty diagnostics offering, and today’s news demonstrates how quickly that investment is adding value to our technology portfolio,” said Dr. Yuh-Geng Tsay, head of Thermo Fisher Scientific’s Specialty Diagnostics business. “Our company continues to push innovation in biomarker discovery and applications. The Copeptin assay shows that we’re having an impact by helping physicians to be more effective at diagnosing disease, which ultimately improves patient health and also lowers the cost of care.”